Remdesivir treatment for patients with moderate to severe COVID-19

BACKGROUND/AIM: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: HASANOĞLU, İmran, GÜNER, Rahmet, ÇELİK, İlhami, KANAT, Fikret, BATIREL, Ayşe, TELLİ DİZMAN, Gülçin, EREN, Esma, YILDIZ SEVGİ, Dilek, BOZKURT, İlkay, KART YAŞAR, Kadriye, ŞENOĞLU, Sevtap, KAZAK, Esra, KARAALİ, Rıdvan, ÇELİKBAŞ, Aysel, PULLUKÇU, Hüsnü, ÇAĞATAY, Arif Atahan, ÜNAL, Serhat, ERDİNÇ, Şebnem, TABAK, Fehmi, GÜL, Ahmet, ALP, Emine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific and Technological Research Council of Turkey (TUBITAK) 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387889/
https://www.ncbi.nlm.nih.gov/pubmed/36326369
http://dx.doi.org/10.55730/1300-0144.5387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387889/
https://www.ncbi.nlm.nih.gov/pubmed/36326369
http://dx.doi.org/10.55730/1300-0144.5387

Ejemplares similares